Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development

The Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI) was held in Madrid, Spain on May 22-25, 2022 and was attended by 157 delegates from 26 countries representing basic and clinical science, regulatory agencies, and pharmaceutical industries. One day of the conference was dedicated to sessions presenting and discussing investigational compounds under development for the treatment of seizures and epilepsy. The current progress report summarizes recent findings and current knowledge for seven of these compounds in more advanced clinical development for which either novel preclinical or patient data are available. These compounds include bumetanide and its derivatives, darigabat, ganaxolone, lorcaserin, soticlestat, STK-001, and XEN1101. Of these, ganaxolone was approved by the US Food and Drug Administration in March 2022 for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients 2 years of age and older.

Automated summary

The Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI) was recently held in Madrid, Spain, where delegates from 26 countries gathered to discuss and present investigational compounds for the treatment of seizures and epilepsy. This progress report focuses on seven compounds in advanced clinical development, including ganaxolone which has been approved by the US FDA for the treatment of seizures associated with CDKL5 deficiency disorder. The report provides a summary of recent findings and current knowledge on these compounds.